# NRC Health (NRC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $21.53, market value $476 million.

## Valuation
- **P/E (trailing): 89.7×** (5-yr avg 19.5×, 3-yr avg 15.3×). NRC Health trades at 89.7× trailing earnings, well above its own five-year average of 19.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 20.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.4×**. Each dollar of revenue is priced at 3.4×.
- **Price / book: 72.7×**. The shares trade at 72.7× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 23.4×**. Enterprise value is 23.4× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 4.5%** (5-yr avg 3.7%). Free cash flow equals 4.5% of the market value, above its five-year average of 3.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 1.1%**. The inverse of the P/E: 1.1% of the price is earned each year.

## Profitability
- **Operating margin: 10.5%**. 10.5% of revenue is left after running the business.
- **Net margin: 8.4%**. 8.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 82.9%**. A 82.9% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 13.7%**. Return on all capital, debt included, is 13.7%.
- **Return on assets: 4.3%**. Each dollar of assets produces 4.3% of profit.

## Growth
- **Revenue growth (1 yr): -4.0%** (3-yr -3.2%/yr, 5-yr 0.6%/yr). Revenue fell 4.0% over the last year, against 0.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 4707.7%** (3-yr 240.2%/yr, 5-yr 103.0%/yr). Earnings per share rose 4707.7%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -15.9%/yr**. Free cash flow has compounded at -15.9% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 5.36**. Debt is 5.36 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 3.0×**. It would take 3.0 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 4.08**. A Z-score of 4.08 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.97%** ($0.60 per share, trailing). NRC Health yields 2.97%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 95%** (59% of free cash flow). 95% of earnings goes out as dividends, leaving a thin cushion.
- **Consecutive years of increases: 1**. 1 straight year of increases.
- **Dividend growth (5 yr): 19.9%/yr** (1-yr 8.3%). The dividend has compounded at 19.9% a year over five years, doubling roughly every 4 years at that pace.

## Price and momentum
- **Total return (1 yr): 48.9%** (YTD 16.7%, 3-mo 13.4%). The shares are up 48.9% over twelve months including dividends.
- **From 52-week high: -9.1%** (95.5% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 0.65** (volatility 57%). Beta of 0.65 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NRC · Page: https://foliofundamentals.com/stocks/nrc

Not investment advice.